Skip to main content

Table 3 Tumor response according to RECIST 1.1, PERCIST 1.0, and histopathology

From: Role of 18 fluorine-fluorodeoxyglucose positron emission tomography/computed tomography in assessment of neoadjuvant chemotherapy response in breast cancer patients

Response No. of patients
RECIST 1.1
 Responders 20 (66.7%)
 Non-responders 10 (33.3%)
PERCIST 1.0
 Responders 23 (76.7%)
  CMR 5 (16.7%)
  PMR 18 (60%)
 Non-responders 7 (23.3%)
  SMD 4 (13.3)
  PMD 3 (10%)
Pathologic response
 Responders 22 (73.3%)
  Grade 3 14 (46.7%)
  Grade 4 4 (13.3%)
  Grade 5 4 (13.3%)
 Non-responders 8 (26.7%)
  Grade 1 1 (3.3%)
  Grade 2 7 (23.3%)